Genetic Testing Could Lead To Better Patient Outcomes
with Targeted Treatments
Introducing Myriad Genetics’ Karen Copeland
Karen Copeland presented at PHEN's June 13th webcast on the topic of BRCA gene mutations in prostate cancer patients, the importance of genetic testing and what the results may mean for these individuals. The discussion covered treatment considerations for patients with these key mutations, along with what role family history can play.
The Triton2 Clinical Trial is Enrolling Patients with BRCA gene mutations who have previously failed chemotherapy.
For patients with metastatic castration-resistant prostate cancer and evidence of genetic changes to their tumors that is confirmed by testing. Patients who continue to experience rising PSA levels despite prior treatment with abiraterone (Zytiga) or enzalutamide (Xtandi) plus chemotherapy are eligible for this study.
The Triton3 Clinical Trial is Enrolling Patients with BRCA gene mutations to test treatment with rucaparib (Rubraca).
For patients with prostate cancer where hormone therapy no longer keeps the PSA from increasing (metastatic castration resistant prostate cancer) with evidence of tumors that are BRCA1, BRCA2, or ATM genetic mutations or alterations